BCL2 and acute myeloid leukemia: Venetoclax is a clinically established BCL‐2 targeting BH3‐mimetic that has FDA approval for use in CLL patients with a 17p deletion and in combination with low‐dose cytarabine or hypomethylating agents, in the treatment of AML [20, 21, 22, 23].